Mankind Pharma Ltd, one of India’s leading pharmaceutical companies, announced a strategic collaboration with Denovo Sciences, a pioneer in artificial intelligence-driven therapeutics. This partnership marks a significant milestone in Mankind Pharma’s commitment to technology-driven innovation and excellence in Research and Development (R&D).
The collaboration will integrate Denovo Sciences’ advanced AI technologies with Mankind Pharma’s deep scientific expertise and robust infrastructure. By leveraging cutting-edge computational models, the joint initiative aims to significantly accelerate the early-stage drug discovery process, optimize candidate selection, and streamline the development of breakthrough innovative therapies.
“This partnership reflects our continued dedication to embracing Next-Gen technology to solve complex healthcare challenges,” said Arjun Juneja, Chief Operating Officer at Mankind Pharma. “By combining our R&D strengths with Denovo’s sophisticated AI capabilities, we aim to transform the timeline and precision of developing novel treatments, ultimately reinforcing India’s position as a serious player in global innovative drug discovery.”
The alliance underscores a shared vision of maximizing therapeutic efficacy and delivery speed, positioning both companies at the forefront of AI-driven pharmaceutical research to better serve global patient needs.
Written by: Pragna Biswas
Graphics by: Pramit Hazra
